Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Featured Videos

Peyronie's disease (PD) is a common condition which results in penile curvature making sexual intercourse difficult or impossible. Collagenase clostridium histolyticum (CCH) is the first licensed drug for the treatment of PD and is indicated in patients with palpable plaque and curvature deformity of at least 30° of curvature. However, only few monocentric studies are available in the current literature and this is the first national multicentric study focusing on this new treatment. In five Italian centres, 135 patients have completed the treatment with three injections of CCH using Ralph's shortened modified protocol. The protocol consisted of three intralesional injections of CCH (0.9 mg) given at 4-weekly intervals in addiction to a combination of home modelling, stretching and a vacuum device on a daily basis. An improvement in the angle of curvature was recorded in 128/135 patients (94.8%) by a mean (range) of 19.1 (0-40)° or 42.9 (0-67)% from baseline (p < 0.001). There was also a statistically significant improvement in all IIEF and PDQ questionnaires subdomains (p < 0.001 in all subdomains). This prospective multicentric study confirms that the three-injection protocol is effective enough to achieve a good result and to minimize the cost of the treatment.

Andrology. 2018 May 07 [Epub ahead of print]

M Capece, A Cocci, G Russo, G Cito, G Giubilei, G Cacciamani, G Garaffa, M Falcone, M Timpano, G Tasso, F Sessa, R Campi, F Di Maida, T Cai, G Morelli, B Giammusso, P Verze, A Palmieri, D Ralph, V Mirone, N Mondaini

Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, Universita degli Studi di Napoli Federico II, Napoli, Italy., Department of Urology, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy., Department of Urology, Universita degli Studi di Catania Scuola di Facolta di Medicina, Catania, Italy., Department of Urology, Azienda USL Toscana centro Sede di Empoli, Empoli, Italy., Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy., The Institute of Urology, London, UK., Department of Urology, Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy., Department of Urology, Santa Chiara Hospital, Trento, Italy., Department of Urology, Università di Pisa, Pisa, Italy., Department of Urology, Ospedale Santa Maria Annunziata, Bagno a Ripoli, Italy.

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 2

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
Calendar
Upcoming educational events
November 23-25, 2018 / European Society for Medical Oncology Asia 2018 Congress
European Society for Medical Oncology Asia 2018 Congress
November 25-30, 2018 / RSNA 2018 Annual Meeting
RSNA 2018 Annual Meeting
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018